Live Breaking News & Updates on வழக்கு விரிவான புற்றுநோய் மையம்|Page 5

Stay updated with breaking news from வழக்கு விரிவான புற்றுநோய் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas

FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Case Western Reserve University , United States , Paolof Caimi , Case Comprehensive Cancer Center , Drug Administration , University Hospitals Cleveland Medical Center , Approval Based , வழக்கு மேற்கு இருப்பு பல்கலைக்கழகம் , ஒன்றுபட்டது மாநிலங்களில் , வழக்கு விரிவான புற்றுநோய் மையம் , பல்கலைக்கழகம் மருத்துவமனைகள் கிளீவ்லேண்ட் மருத்துவ மையம் , ஒப்புதல் அடிப்படையிலானது ,

ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Published: Apr 23, 2021

First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
ZYNLONTA addresses an unmet need across a broad population of third-line (3L)+ r/r patients, including patients with DLBCL not otherwise specified, DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma
ZYNLONTA demonstrated 48.3% overall response rate, 24.1% complete response rate and durable responses in heavily pretreated patients in pivotal LOTIS-2 trial
Investor conference call and webcast to be held Friday, April 23
rd at 4 p.m. ET

LAUSANNE, Switzerland (BUSINESS WIRE) ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA™ (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two ....

United States , New Jersey , City Of , United Kingdom , Lausanne Biop , Paolof Caimi , Chris Martin , Case Comprehensive Cancer Center , Company On Twitter , Patient Support Program , Drug Administration , University Hospitals Cleveland Medical Center , Exchange Commission , Case Western Reserve University , American Cancer Society , Case Western Reserve , Chief Executive Officer , Advancing Patient Support Program , Prescribing Information , San Francisco Bay Area , Accessed March , Etudes Des Lymphomes , Dc Therapeutics Announces Fda Approval Of Zynlonta Loncastuximab Tesirine Lpyl In Relapsed Or Refractory Diffuse Largeb Cell Lymphoma , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜெர்சி , நகரம் ஆஃப் ,

ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , New Jersey , City Of , United Kingdom , Lausanne Biop , Annie Starr , Paolof Caimi , Eugenia Litz , Amanda Hamilton , Chris Martin , Case Comprehensive Cancer Center , Company On Twitter , Patient Support Program , Drug Administration , University Hospitals Cleveland Medical Center , Exchange Commission , Dynamics Group , Case Western Reserve University , American Cancer Society , Case Western Reserve , Chief Executive Officer , Advancing Patient Support Program , Prescribing Information , San Francisco Bay Area , Accessed March , Etudes Des Lymphomes ,

New Antibody-Drug Conjugate OK'd in DLBCL

email article
The FDA has granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.
Loncastuximab tesirine is an antibody-drug conjugate (ADC), comprised of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to the pyrrolobenzodiazepine dimer cytotoxin.
Approval was based on response data from the single-arm phase II LOTIS-2 trial for the treatment of adults with relapsed or refractory DLBCL following two or more lines of systemic therapy.
Among 145 patients, the drug demonstrated an overall response rate of 48.3%, a complete response rate of 24.1%, and a partial response rate of 24.1%. Median time to response was 1.3 months, while the median duration of response for the 70 responders was 10.3 months (inclusive of patients who were censored). ....

Paolof Caimi , Case Comprehensive Cancer Center , University Hospitals Cleveland Medical Center , வழக்கு விரிவான புற்றுநோய் மையம் , பல்கலைக்கழகம் மருத்துவமனைகள் கிளீவ்லேண்ட் மருத்துவ மையம் ,

ADC Therapeutics SA: ADC Therapeutics Announces FDA Approval of ZYNLONTA (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(0)
First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
ZYNLONTA addresses an unmet need across a broad population of third-line (3L)+ r/r patients, including patients with DLBCL not otherwise specified, DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma
ZYNLONTA demonstrated 48.3% overall response rate, 24.1% complete response rate and durable responses in heavily pretreated patients in pivotal LOTIS-2 trial
Investor conference call and webcast to be held Friday, April 23
rd at 4 p.m. ET
ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBC ....

United States , New Jersey , City Of , United Kingdom , Lausanne Biop , Annie Starr , Paolof Caimi , Eugenia Litz , Amanda Hamilton , Chris Martin , Case Comprehensive Cancer Center , Company On Twitter , Patient Support Program , Drug Administration , University Hospitals Cleveland Medical Center , Exchange Commission , Dynamics Group , Case Western Reserve University , American Cancer Society , Case Western Reserve , Chief Executive Officer , Advancing Patient Support Program , Prescribing Information , Fetal Toxicity , San Francisco Bay Area , Accessed March ,